Search Results

Biotech Beach

FDA Grants EUA to Wondfo’s WELLlife™ COVID-19/Influenza A&B Test Supported by DCN Dx Clinical Research

DCN Dx, a leading contract research organization for in vitro diagnostics, today acknowledges the FDA’s Emergency Use Authorization (EUA) of the WELLlife™ COVID-19/Influenza A&aB Test, developed by Wondfo USA.

May 15, 2024

·

3 min read

Business

DCN Dx Bolsters Board with Appointment of Former Meridian Biosciences CEO Jack Kenny

DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, announces the appointment of industry veteran Jack Kenny to its board of directors.

March 12, 2024

·

2 min read

Press Releases

DCN Dx’s Clinical Research Helps Secure FDA Authorization for Cepheid HCV Test

July 10, 2024

·

2 min read

Biotech Beach

DCN Dx and Mapp Biopharmaceutical Announce Subcontract

DCN Dx announced a subcontract with Mapp Biopharmaceutical, Inc., a developer of novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

February 1, 2023

·

3 min read

Policy

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Co-Diagnostics, Inc. announced that the Company has completed its first U.S. Food and Drug Administration application for 510 clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter use.

June 14, 2024

·

4 min read

Business

Reveal Genomics® to Evaluate Prospective Real-time Performance of HER2DX® Genomic Test in the United States

Reveal Genomics® to Evaluate Prospective Real-time Performance of HER2DX ® Genomic Test in the United States.

June 18, 2024

·

4 min read

Reveal Genomics® HER2DX® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer

Reveal Genomics ® HER2DX ® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer.

June 27, 2024

·

5 min read

QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care

QIAGEN announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States.

June 3, 2024

·

8 min read

BioMed Diagnostics to Attend VMX 2024

BioMed Diagnostics, a leader in microbiological testing and a DCN Dx brand, is pleased to announce their attendance at VMX 2024.

January 9, 2024

·

3 min read

Biotech Bay

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD Cowen 3rd Annual Tools / Dx Revolution Conference on Tuesday, June 25, 2024 at 5:30 p.m. Eastern Time.

June 18, 2024

·

1 min read